Soranib (Sorafenib) is the newest drug, a multi-kinase inhibitor with antitumor effect. Sorafenib has a suppressive effect on tumor growth and is used in the treatment of metastatic renal cell and hepatocellular carcinoma. It can reduce the risks of further disease progression and prolong life with such diagnoses as primary liver cancer or hepatocellular carcinoma. The drug is used in more than 100 countries.
Nexavar is the newest drug, a multi-kinase inhibitor, which has an antitumor effect. Sorafenib has a suppressive effect on tumor growth. Nexavar is used in the treatment of metastatic renal cell and hepatocellular carcinoma.
The conducted studies have established the effectiveness of the drug – Nexavar is able to reduce the risks of further disease progression and prolong life with such diagnoses as primary liver cancer or hepatocellular carcinoma. The drug is used in more than 100 countries. The use of Nexavar is also topical as a substitute for interferon-alpha and interleukin therapy in those patients who, due to various factors, are contraindicated or not helped by this treatment. The use of Nexavar is also possible as a first-line therapy for inoperable and locally advanced and disseminated kidney cancer, as well as the 2nd line for the treatment of non-cell carcinoma of the kidney and tumors that are immune to cytokines.
Inside. The recommended dose is 800 mg/day. Nexavar can be taken on an empty stomach, and with food. It is desirable that the food does not contain a large amount of fat, as it helps reduce the bioavailability of sorafenib.
Treatment with Nexavar is stopped if the clinical effect disappears.
The drug should also be discontinued if an unacceptable toxic effect occurs on the background of Nexavar’s treatment.
Dose reduction up to 400 mg/day may be required if there are various side effects.
There are no data on the use of Nexavar in patients with impaired hepatic function and in patients who are on hemodialysis.
Treatment Nexavar conducted under the supervision of a doctor who has experience with antitumor therapy.
During the whole course of Nexavar’s intake, it is required to observe the parameters of peripheral blood (leukocyte formula and platelets).
Most often, adverse reactions to Nexavar were skin reactions, especially in the limbs, and rashes. As a rule, they were the first or second degree of severity, and their manifestation was noted during the first 6 weeks of therapy. Such undesirable reactions can be quenched by lowering the dose of Nexavar, the appropriate treatment. With repeated repetition of these side effects, as well as in case of their severe manifestation, treatment with sorafenib cannot be continued.
During the course of Nexavar’s intake, it is necessary to regularly monitor the patient’s blood pressure to prevent the development of hypertension. If necessary, prescribe antihypertensive drugs. With the development of severe or persistent hypertension is possible to cancel the drug.
When Nexavar is prescribed in combination with warfarin, prothrombin time, INR and clinical signs of bleeding should be regularly determined.
For the appointment or resumption of therapy with the use of Nexavar in the case of surgical interventions requires a special solution, which should be based on an assessment of the adequacy of wound healing.
Questions and answers of the customers
There are no questions yet, be the first to ask something for this product.